Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases

BMJ Case Reports

Volumn , Issue , 2014, Pages

  Torres, Sofia ^a   Maralani, Pejman ^b   Verma, Sunil ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; PACLITAXEL; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ADJUVANT THERAPY; ADULT; ARTICLE; AXILLARY LYMPH NODE; BALANCE IMPAIRMENT; BONE METASTASIS; BRAIN METASTASIS; BRAIN RADIATION; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; DISEASE CONTROL; DISEASE FREE INTERVAL; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HER 2 POSITIVE BREAST CARCINOMA; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MASTECTOMY; MENINGEAL METASTASIS; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOPHOBIA; PLEURA METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC THERAPY; TUMOR EMBOLISM; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

EID: 84907323460     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2014-205680     Document Type: Article

References (6)

1. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009;27:5278-86.
2. Stemmler HJ, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer with brain metastases and impaired blood-brain barrier. Anticancer Drugs 2007;18:23-8. (Pubitemid 44949792)
3. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from Her2-positive breast cancer. Clin Cancer Res. 2009;15:1452-9.
4. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
5. Krop I, Lin N, Blackwell K, et al. Efficacy and safety of trastuzumab emtansine (T-DM1) vs lapatinib plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer and central nervous system metastases: results from a retrospective exploratory analysis of EMILIA. Poster Presentation, SABCS, 2013.
6. Bartsch R, Berghoff AS, Preusser M. Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J Neurooncol 2014;116:205-6.